Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results  ●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and...